Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigation of Activated Factor XII (Fxlla) as a Prognostic Marker.

NCT00521976 is registered in ClinicalTrials.gov with Helse Stavanger HF as lead sponsor.

NCT NCT00521976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00521976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigation of Activated Factor XII (Fxlla) as a Prognostic Marker.
Lead sponsor
Helse Stavanger HF
Phase
Observational
Overall status
Completed
Start date
November 30, 2002
Completion date
December 31, 2005
Enrollment
871 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chest pain, coronary artery disease, myocardial infarction, unstable angina pectoris